Highline Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Highline Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-11,087	Closed	-$11M	–	33
2019 Q1	$11M	Sell	11,087 -9,648	-47%	-$8.96M	0.69%	30
2018 Q4	$18M	Buy	20,735 +11,639	+128%	+$10.8M	1.21%	25
2018 Q3	$9.4M	Hold	9,096	–	–	0.43%	29
2018 Q2	$8.36M	Buy	+9,096	New	+$9.77M	0.28%	39

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Highline Capital Management's ATRA Position: Q2 2019 in Review

Highline Capital Management sold out of Atara Biotherapeutics (ATRA) in Q2 2019, closing a stake of 11,087 shares — an estimated $11M sold.

Highline Capital Management first reported a position in ATRA in Q2 2018 and held it in 4 quarters. The position peaked at $18M in Q4 2018. 116 funds tracked by Wall St. Rank hold ATRA as of Q2 2019.

Highline Capital Management reported no remaining Atara Biotherapeutics position as of Q2 2019 after selling out during the quarter.
Highline Capital Management sold 11,087 Atara Biotherapeutics shares in Q2 2019, an estimated $11M.
Highline Capital Management first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 4 quarters.
Highline Capital Management's Atara Biotherapeutics position peaked at $18M in Q4 2018.
116 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2019.

Based on Highline Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.